Hikma signs on to sell Theravance's Vibativ; Sanofi nabs Japanese nod for Lyxumia;

 @FiercePharma: Fresenius Kabi yanks four lots of benztropine mesylate on risk of glass particles, stops distribution to investigate. News | Follow @FiercePharma

 @EricPFierce: ICYMI: FDA approves first non-hormonal treatment for hot flashes. Release | Follow @EricPFierce

> Hikma Pharmaceuticals inked a deal to commercialize Theravance's ($THRX) treatment for drug-resistant staph infections, Vibativ, in the Middle East and Africa. Release

> Sanofi ($SNY) won Japanese approval for its new diabetes drug Lyxumia; its application for U.S. approval is still pending. Report

> GlaxoSmithKline ($GSK) moved 150 research projects back to the U.K. to take advantage of the new "patent box" tax rate of 10%. Report

> Fresenius Kabi's U.S. unit recalled four lots of its benztropine mesylate injection on the possibility of glass particles in drug vials and stopped distributing the products pending an investigation. Report

> India's Aurobindo Pharma signed a deal with the Medicines Patent Pool to produce medicines for treating children with HIV. Report

> Pharming agreed to collaborate with a Sinopharm subsidiary on selling the Dutch biotech's angioedema drug Ruconest/Rhucin and developing other treatments. Report

Medical Device News

 @FierceMedDev: Veracyte nails $28M Series C. Story | Follow @FierceMedDev

 @MarkHFierce: There's still time to submit your nomination for this year's FMD Fierce 15. More | Follow @MarkHFierce

 @DamianFierce: Thoratec is spending up to $56.5M for Terumo's in-development heart device. News | Follow @DamianFierce

> Malaysia's new device regs poised to heighten the competition. Article

> A drug-free Covidien is now all about devices. Story

> Zyomyx pulls in $12M to advance low-cost HIV Dx to finish line. More

Biotech News

 @FierceBiotech: Insmed shares routed on head-to-head antibiotic Phase III results. Story | Follow @FierceBiotech

 @JohnCFierce: The FDA's suvorexant decision was expected. I don't see how weak suvo competes with the generics. It'll be an alternative for non-response. | Follow @JohnCFierce

 @RyanMFierce: Onyx is following the M&A resistance strategy, which Termeer and more recently Martin have used. More | Follow @RyanMFierce

> FDA scraps Merck's high-dose sleep drug, demands weaker version. Story

> Report: China rounds up GlaxoSmithKline staffers in corruption probe. Article

CRO News

> MMS teams up with Datatrak for eClinical heft. Story

> Want to work with Roche? Prepare for high standards. More

> AstraZeneca taps Sarah Cannon for cancer R&D. Article

Biotech IT News

> Ex-Googlers bring Big Data analytics to oncology. News

> Deloitte turns EHR reservoir into health outcomes tool. Article

> J&J teams up with Mount Sinai on bioinformatics project. Story

> Data secrecy and outdated tech exacerbating drug shortages. More

And Finally... The World Health Organization called for earlier treatment of patients diagnosed with HIV infection; under new guidelines, 26 million patients would need treatment worldwide. Report